NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Ma ...

LOS ANGELES, April 24, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Sarepta admitted on March 18, 2025, that a young patient with Duchenne ...

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws related to Sarepta Therapeutics following the death of a patient after treatment with its gene therapy, ELEVIDYS [1][2]. Group 1: Company Overview - Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is facing scrutiny after a 16-year-old boy died from acute liver failure post-treatment with its gene therapy [1]. - The company's stock price experienced a significant decline of $27.81 per share, or 27.44%, closing at $73.54 per share on March 18, 2025, following the news of the patient's death [2]. Group 2: Legal Investigation - Kessler Topaz Meltzer & Check, LLP is actively investigating the situation on behalf of Sarepta investors, focusing on potential securities law violations [1]. - The law firm has a history of prosecuting class actions related to securities fraud and has recovered billions for investors [3].

Shares of Sarepta Therapeutics (SRPT) dropped more than 6% yesterday after the EMA placed a clinical hold on all studies evaluating Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy (DMD). The therapy has been developed in collaboration with pharma giant Roche (RHHBY) .This hold has been placed in response to a patient’s death post-treatment with Elevidys, which was reported last month. Though the death was due to acute liver failure (a known risk of Elevidys), Sarepta believes that the pa ...

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fid ...

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On M ...

Core Viewpoint - Sarepta Therapeutics is facing significant challenges, particularly following a 20% drop in share price due to concerns surrounding its key product, Elevidys, after a patient suffered fatal liver failure [1][5]. Group 1: Company Overview - Sarepta Therapeutics specializes in gene therapies for Duchenne muscular dystrophy (DMD), with Elevidys being its most important product targeting the genetic causes of the disorder [3]. - Elevidys received full U.S. approval for ambulatory DMD patients aged 4 and older, but is under accelerated approval for non-ambulatory patients, requiring further clinical trials to confirm efficacy [4]. Group 2: Recent Developments - A young patient treated with Elevidys experienced fatal acute liver failure, raising concerns about the treatment's safety, despite liver injury being a known risk [5]. - In Q4, Sarepta reported revenue of $658.4 million, a 66% increase year-over-year, with Elevidys contributing $384.2 million, accounting for over 50% of total revenue [5]. Group 3: Market Reaction and Future Outlook - The market reacted negatively to the news of the patient death, creating uncertainty around Elevidys' future sales and prescribing trends [5][7]. - Despite the incident, the company noted that the patient had a recent cytomegalovirus infection, which could have contributed to the liver failure, suggesting that the situation may not be solely attributable to Elevidys [6]. - The worst-case scenario would involve regulators pulling Elevidys from the market, but this is considered unlikely due to the lack of alternative effective treatments for DMD [7]. - Sarepta has other DMD treatments in development, but Elevidys was expected to be the primary growth driver, making the current uncertainty a risk for the company's stock [8].

Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in SRPT over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking ...

Sarepta Therapeutics (SRPT) shares soared 8.7% in the last trading session to close at $79.97. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 30.2% loss over the past four weeks.This rise in share price can be attributed to the recovery in Sarepta’s share price after it tanked earlier this week on reports of a patient’s death following treatment with Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy.This biopha ...

Core Viewpoint - Sarepta Therapeutics' stock experienced a significant decline of over 20% following the report of a patient's death after receiving Elevidys, its gene therapy for Duchenne muscular dystrophy (DMD) [1][4]. Company Overview - The patient who died was reported to have suffered from acute liver failure, a known risk associated with Elevidys. This incident marks the first death linked to the therapy, although the patient also had a recent CMV infection that may have contributed to the liver damage [2][3]. - Sarepta has communicated the event to health authorities and plans to update the prescribing information for Elevidys. The company asserts that the overall benefit-risk profile of the therapy remains positive, with over 800 patients treated [3]. Financial Impact - The decline in Sarepta's stock is attributed to concerns that this incident may deter doctors from prescribing Elevidys, potentially slowing its market adoption. Elevidys accounted for nearly 60% of the company's total revenues in Q4 2024, with projected net product revenues for the year between $2.9 billion and $3.1 billion, two-thirds of which are expected from Elevidys sales [4]. - Year-to-date, Sarepta's shares have decreased by nearly 40%, contrasting with a 6% growth in the industry [5]. Product Portfolio - Sarepta's portfolio includes four approved therapies for DMD, with Elevidys being the first one-shot gene therapy for the condition in the U.S. Since its launch in June 2023, Elevidys has shown significant sales potential, generating approximately $821 million in 2024 compared to $200 million in the previous year [7]. - The company has a partnership with Roche for the development of Elevidys, which has exclusive rights to market the therapy outside the U.S. [8]. - Other therapies in Sarepta's portfolio include Exondys 51, Vyondys 53, and Amondys 45, which collectively have the potential to address nearly one-third of all DMD patients in the U.S. [9].